We recently published a significant survival decreasing effect of the NF-κB Inhibitor dexamethasone and pyrrolidine dithiocarbamate (PDTC) in CSCs derived from non-small cell lung cancer, which may also affect endometrial CSCs with elevated NF-κB activity [65]. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.